



## Sae Won Kim

ProGen Co. Ltd., Korea

### • Education

Period	Affiliation	Position
- 2007~2014	Pohang University of Science and Technology (POSTECH)	Ph.D.
- 2003~2007	Johns Hopkins University	B.S.

### • Affiliations / Experience

Period	Affiliation	Position
- 2023-Present	ProGen Co., Ltd.	Director
- 2023-Present	Yonsei University, College of Medicine	Adjunct Professor
- 2023-2023	SL MetaGen, Inc.	Chief Business Officer
- 2014-2023	SL BiGen, Inc.	Chief Scientist

### • Publications

- Hwang I, Jin HT, Kang MC, Kim TY, Sung YC, Kim SW. Generation and functional characterization of a multigene-modified NK101 cell line exerting diverse mechanisms of antitumor action. *OncolImmunology* 2022;11(1):2014655
- Kim SW, Park HW, Kim H, Lee S, Choi SY, Park Y, Lee SW. Evaluating Antitumor Activity of Kiatomab by Targeting Cancer Stem Cell-Specific KIAA1114 Antigen in Mice. *Immune Network* 2019 Nov 19;19(6):e43
- Yang HG, Kang MC, Kim TY, Hwang I, Jin HT, Sung YC, Eom KS, Kim SW. Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy. *Journal for ImmunoTherapy of Cancer* 2019; 7(1):138
- Kim SW, Yang HG, Kang MC, Lee S, Namkoong H, Lee SW, Sung YC. KIAA1114, a full-length protein encoded by the trophinin gene, is a novel surface marker for isolating tumor-initiating cells of multiple hepatocellular carcinoma subtypes. *Oncotarget* 2014; 5(5):1226-40
- Kim SW, Kim SJ, Park SH, Yang HG, Kang MC, Choi YW, Kim SM, Jeun SS, Sung YC. Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK. *Clinical Cancer Research* 2013; 19(2):415-27